Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax Universe Fund of Option Income ETFs (YMAX) vs Zoetis Inc (ZTS) Price & Performance

YieldMax Universe Fund of Option Income ETFsTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

YieldMax Universe Fund of Option Income ETFs vs Zoetis Inc — how do they compare? YieldMax Universe Fund of Option Income ETFs trades at $7.53, while Zoetis Inc trades at $73.51 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals.

YMAXZTS
Sector
Income / Options OverlayHealth
52-Week High
$13.14$150.61
52-Week Low
$7.27$71.91
Market Cap
$30.40B
Enterprise Value
$37.96B
Dividend Yield
2.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax Universe Fund of Option Income ETFs

YMAX trades at $7.70 with a slight 0.13% daily gain, showing modest positive momentum. The technical outlook is bullish with moving averages supporting upward movement, though oscillators remain neutral. Recent news highlights the fund's weekly dividend distributions but also raises concerns about NAV erosion and sustainability of the high-yield strategy. The fund's structure as a fund-of-funds adds layers of costs that impact overall returns.

YMAX faces significant challenges with declining share price despite high distributions, suggesting the current yield may be unsustainable. The fund's principal erosion and structural cost issues present substantial risks for income-focused investors. While technical indicators show short-term bullish signals, fundamental concerns about the distribution policy and NAV performance warrant cautious consideration for long-term investment viability.

Zoetis Inc

Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.

The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax Universe Fund of Option Income ETFs

YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.

Read more on YMAX

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS